CA2608163C - Hydralazine compositions and methods - Google Patents

Hydralazine compositions and methods Download PDF

Info

Publication number
CA2608163C
CA2608163C CA2608163A CA2608163A CA2608163C CA 2608163 C CA2608163 C CA 2608163C CA 2608163 A CA2608163 A CA 2608163A CA 2608163 A CA2608163 A CA 2608163A CA 2608163 C CA2608163 C CA 2608163C
Authority
CA
Canada
Prior art keywords
further embodiments
macular degeneration
subject
compound
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2608163A
Other languages
English (en)
French (fr)
Other versions
CA2608163A1 (en
Inventor
George C. Chiou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Publication of CA2608163A1 publication Critical patent/CA2608163A1/en
Application granted granted Critical
Publication of CA2608163C publication Critical patent/CA2608163C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2608163A 2005-05-12 2006-05-04 Hydralazine compositions and methods Expired - Fee Related CA2608163C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68099805P 2005-05-12 2005-05-12
US60/680,998 2005-05-12
US77642606P 2006-02-24 2006-02-24
US60/776,426 2006-02-24
US11/416,773 2006-05-03
US11/416,773 US8088773B2 (en) 2005-05-12 2006-05-03 Therapeutic compositions and methods
PCT/US2006/017329 WO2006124324A1 (en) 2005-05-12 2006-05-04 Therapeutic compositions and methods

Publications (2)

Publication Number Publication Date
CA2608163A1 CA2608163A1 (en) 2006-11-23
CA2608163C true CA2608163C (en) 2011-10-25

Family

ID=37431545

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2608163A Expired - Fee Related CA2608163C (en) 2005-05-12 2006-05-04 Hydralazine compositions and methods

Country Status (9)

Country Link
US (5) US8088773B2 (https=)
EP (3) EP2508183B1 (https=)
JP (2) JP5335419B2 (https=)
AU (1) AU2006247892B2 (https=)
CA (1) CA2608163C (https=)
DE (1) DE202006020318U1 (https=)
ES (1) ES2598277T3 (https=)
PL (1) PL2508182T3 (https=)
WO (1) WO2006124324A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709977A2 (pt) * 2006-04-14 2011-08-02 Novartis Ag uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos
US7736860B2 (en) * 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
PL2470191T3 (pl) 2009-08-24 2014-09-30 Stealth Peptides Int Inc Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
KR20150032552A (ko) * 2012-06-11 2015-03-26 매큐클리어 인코포레이션 치료 제제 및 치료 방법
JP2015531785A (ja) * 2012-09-13 2015-11-05 シービーエー・ファーマ・インコーポレイテッドＣｂａ Ｐｈａｒｍａ，Ｉｎｃ． テトランドリン医薬製剤及び方法
JP6453216B2 (ja) 2013-07-23 2019-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ縮合環化合物
US9370503B1 (en) * 2015-02-26 2016-06-21 Chi Chou Liao Compounds for treating ocular diseases
CA3085331A1 (en) 2017-12-11 2019-06-20 Artelo Biosciences, Inc. New solid forms of cannabidiol and uses thereof
JP7089603B2 (ja) * 2018-06-11 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼疾患を治療するための脱メチル化
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
EP3949958A1 (en) * 2020-08-04 2022-02-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound for the treatment and prophylaxis of a lipofuscin-associated disease
CN114276251B (zh) * 2021-12-07 2022-12-16 武汉大学 一种合成硝基(杂)芳烃的方法
US20240285572A1 (en) * 2023-02-27 2024-08-29 Opticgon Llc Compositions comprising nitric oxide-releasing compounds for treating choroidal vascular diseases and methods of their use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) * 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
FI873429L (fi) * 1986-08-18 1988-02-19 Houston Biotechnology Oftalmologiska kompositioner foer behandling av nervdegenerationer.
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
IT1201151B (it) * 1987-01-14 1989-01-27 Indena Spa Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5194434A (en) * 1991-12-03 1993-03-16 Texas A&M University System Use of OB-101 to treat ocular inflammation
US5252607A (en) * 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5422166A (en) * 1993-02-12 1995-06-06 Wangner Systems Corporation Abrasion resisting edge for a forming fabric
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
EP0911027A4 (en) * 1996-04-26 2000-11-29 Fujisawa Pharmaceutical Co THE DIHYDROPYRIDINE CONTAINS TO IMPROVE THE CIRCULATION OF THE EYE-SURROUNDING TISSUE
AU4582797A (en) * 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
CA2270119A1 (en) * 1996-10-28 1998-05-07 Senju Pharmaceutical Co., Ltd. Drugs for ameliorating ocular circulatory disorders
AU741525B2 (en) * 1998-03-06 2001-12-06 Board Of Regents, The University Of Texas System Composition and method for treating macular disorders
US6028099A (en) * 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
EP1161686A2 (en) * 1999-03-05 2001-12-12 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) * 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP4372905B2 (ja) * 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) * 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
JP2004250347A (ja) * 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および／又は予防剤
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1814535A4 (en) * 2004-11-08 2008-06-04 Nitromed Inc NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES

Also Published As

Publication number Publication date
JP5643263B2 (ja) 2014-12-17
EP1885371A4 (en) 2010-04-07
HK1177419A1 (en) 2013-08-23
EP2508182B1 (en) 2016-07-06
JP2012229257A (ja) 2012-11-22
US20120196868A1 (en) 2012-08-02
US20060276458A1 (en) 2006-12-07
CA2608163A1 (en) 2006-11-23
PL2508182T3 (pl) 2017-05-31
US20130059841A1 (en) 2013-03-07
US20120071485A1 (en) 2012-03-22
EP1885371A1 (en) 2008-02-13
US8088773B2 (en) 2012-01-03
JP5335419B2 (ja) 2013-11-06
JP2008540528A (ja) 2008-11-20
EP2508182A1 (en) 2012-10-10
EP2508183A1 (en) 2012-10-10
WO2006124324A1 (en) 2006-11-23
US20120115959A1 (en) 2012-05-10
US8318741B2 (en) 2012-11-27
EP2508183B1 (en) 2014-07-09
ES2598277T3 (es) 2017-01-26
AU2006247892A1 (en) 2006-11-23
AU2006247892B2 (en) 2010-04-22
DE202006020318U1 (de) 2008-07-31

Similar Documents

Publication Publication Date Title
US8318741B2 (en) Therapeutic compositions and methods
Marquis et al. Management of glaucoma: focus on pharmacological therapy
Brown et al. ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery
Giangiacomo et al. The effect of preoperative subconjunctival triamcinolone administration on glaucoma filtration: I. Trabeculectomy following subconjunctival triamcinolone
MXPA04004363A (es) Procedimientos para tratar enfermedades neovasculares oculares.
WO1993024121A1 (fr) Medicament pour le glaucome
WO1989010757A1 (en) New ophthalmic preparation for treating glaucoma
Meyer et al. 3. Phenylenhrine hydrochloride
Adler et al. Ocular effects of cannabinoids
JP2007527417A (ja) 白内障、黄斑変性および他の眼疾患の改善
Dietrich Feline glaucomas
van der Woerdt Management of intraocular inflammatory disease
Saxena et al. Pharmacotherapy of glaucoma
JP2001519394A (ja) 緑内障の局所治療用フルナリジンの使用法
HK1177420A (en) Hydralazine for use in the treatment of age-related macular degeneration
HK1177419B (en) Interleukin-1 blocker for use in the treatment of age-related macular degeneration
HK1177420B (en) Hydralazine for use in the treatment of age-related macular degeneration
RU2238707C1 (ru) Способ хирургического лечения открытоугольной глаукомы
KR20030087029A (ko) 스테로이드를 유효 성분으로 하는 망맥락막 질환 치료제
Moore 8 Chapter Anticholinergic Agents (Parasympatholytics)
Kozobolis et al. Combined cataract-glaucoma surgery
JP2002356431A (ja) ステロイドを有効成分とする網脈絡膜疾患治療剤
Jindra Open-angle glaucoma: diagnosis and therapy
Jindra Open-angle glaucoma: diagnosis and management
Sampaolesi et al. Medical Therapy in Glaucoma

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190506